participant.ui.study.eligibility-status-cta.not-recruiting
common.study.topics.clinical

Testing Treatment for Prostate Cancer

common.study.values.description

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

The purpose of this study is to determine the benefit and safety of relugolix 120 mg orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (a?$ 50 ng/dL [1.7 nmol/L] in participants with androgen-sensitive advanced prostate cancer.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Relugolix

Relugolix 120 mg tablet administered orally once daily following an oral loading dose of 360 mg on Day 1

Drug - Leuprolide Acetate

Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in some Asian countries), every 3-months by subcutaneous or intramuscular injection

participant.views.study.view.additional

participant.views.study.view.scientific-title

HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

common.study.values.clinical-trial-id

NCT03085095

participant.views.study.view.id

PdyvPe